CRK (CRK proto-oncogene, adaptor protein)
- symbol:
- CRK
- locus group:
- protein-coding gene
- location:
- 17p13.3
- gene_family:
- SH2 domain containing
- alias symbol:
- None
- alias name:
- None
- entrez id:
- 1398
- ensembl gene id:
- ENSG00000167193
- ucsc gene id:
- uc002fsl.4
- refseq accession:
- NM_016823
- hgnc_id:
- HGNC:2362
- approved reserved:
- 1992-12-07
CRK基因属于CRK基因家族，该家族还包括CRKL等成员，它们编码的蛋白质是重要的衔接蛋白，在细胞信号转导中发挥关键作用。CRK蛋白含有SH2和SH3结构域，能够介导蛋白质间的相互作用，参与调控细胞增殖、分化、迁移和凋亡等过程。CRK蛋白通过SH2结构域与磷酸化的酪氨酸残基结合，通过SH3结构域招募下游效应分子，如SOS、C3G等，从而激活RAS-MAPK和JNK等信号通路。CRK在多种组织中表达，尤其在发育和免疫系统中具有重要作用。CRK基因突变或表达异常与多种疾病相关，包括癌症、心血管疾病和免疫系统疾病。在癌症中，CRK的过表达常与肿瘤侵袭、转移和不良预后相关，因为它能增强细胞迁移和侵袭能力，促进上皮-间质转化（EMT）。CRK过表达还可能激活PI3K-AKT和RAS-ERK通路，促进细胞存活和增殖。相反，CRK表达降低可能抑制肿瘤生长和转移，但同时也可能影响正常细胞的信号转导和功能。CRK基因家族成员的共性在于它们都含有SH2和SH3结构域，能够介导多种信号通路的蛋白质相互作用，调控细胞行为。CRK与CRKL在功能上有部分冗余，但也存在特异性。例如，CRKL在BCR-ABL融合蛋白的信号转导中起重要作用，与慢性髓性白血病（CML）的发生相关。此外，CRK在神经系统发育中也发挥作用，其表达异常可能与神经发育障碍有关。研究表明，CRK还与炎症反应和免疫调节相关，可能通过调控T细胞和巨噬细胞的功能影响免疫应答。总之，CRK基因是一个多功能的信号转导调控因子，其表达水平和活性变化对细胞行为和机体健康具有广泛影响。
This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008]
这个基因编码的衔接蛋白家族结合几个酪氨酸磷酸化的蛋白质的成员。该基因的产物具有几个SH2和SH3结构域（SRC-同源结构域），并参与几个信号传导途径，在酪氨酸激酶通过SH2磷酸酪氨酸相互作用附近招募胞质蛋白。这种蛋白质的功能的N-末端SH2结构域作为变换而C末端SH3域函数作为变换的负调节的正调节。编码具有不同的生物活性的不同的同种型两种备选的转录已经描述。 [由RefSeq的，2008年7月提供]
基因本体信息
CRK基因（以及对应的蛋白质）的细胞分布位置：
- 质膜
- 细胞质
- 细胞外
- 高尔基体
- 囊泡
- 细胞骨架
- 内质网
- 细胞核
- 内体
- 溶酶体
- 线粒体
CRK基因的本体（GO）信息：
| 名称 |
|---|
| 4015 Rap1 signaling pathway [PATH:hsa04015] |
| 4010 MAPK signaling pathway [PATH:hsa04010] |
| 4012 ErbB signaling pathway [PATH:hsa04012] |
| 4810 Regulation of actin cytoskeleton [PATH:hsa04810] |
| 4510 Focal adhesion [PATH:hsa04510] |
| 4666 Fc gamma R-mediated phagocytosis [PATH:hsa04666] |
| 4062 Chemokine signaling pathway [PATH:hsa04062] |
| 4910 Insulin signaling pathway [PATH:hsa04910] |
| 4722 Neurotrophin signaling pathway [PATH:hsa04722] |
| 5200 Pathways in cancer [PATH:hsa05200] |
| 5206 MicroRNAs in cancer [PATH:hsa05206] |
| 5220 Chronic myeloid leukemia [PATH:hsa05220] |
| 5211 Renal cell carcinoma [PATH:hsa05211] |
| 5131 Shigellosis [PATH:hsa05131] |
| 5100 Bacterial invasion of epithelial cells [PATH:hsa05100] |
| 名称 |
|---|
| ARMS-mediated activation |
| Cytokine Signaling in Immune system |
| Downstream signal transduction |
| Fcgamma receptor (FCGR) dependent phagocytosis |
| Hemostasis |
| Immune System |
| Innate Immune System |
| Insulin receptor signalling cascade |
| Integrin alphaIIb beta3 signaling |
| Interleukin-3, 5 and GM-CSF signaling |
| NGF signalling via TRKA from the plasma membrane |
| p130Cas linkage to MAPK signaling for integrins |
| Platelet activation, signaling and aggregation |
| Platelet Aggregation (Plug Formation) |
| Prolonged ERK activation events |
| Regulation of actin dynamics for phagocytic cup formation |
| Regulation of signaling by CBL |
| Signal attenuation |
| Signal Transduction |
| Signaling by Insulin receptor |
| Signaling by Interleukins |
| Signaling by PDGF |
| Signaling by VEGF |
| Signalling by NGF |
| Signalling to ERKs |
| VEGFA-VEGFR2 Pathway |
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Myocardial Ischemia | 0.12 | 1 | 0 | CTD_human |
| Breast Carcinoma | 0.007328931 | 27 | 0 | BeFree |
| Malignant neoplasm of breast | 0.007057489 | 26 | 0 | BeFree |
| Lung Neoplasms | 0.005991584 | 3 | 0 | BeFree_LHGDN |
| Glioblastoma | 0.004624443 | 8 | 0 | BeFree_LHGDN |
| Rheumatoid Arthritis | 0.003800186 | 14 | 0 | BeFree |
| Malignant neoplasm of prostate | 0.003800186 | 14 | 0 | BeFree |
| Prostate carcinoma | 0.003800186 | 14 | 0 | BeFree |
| Malignant neoplasm of lung | 0.003800186 | 14 | 0 | BeFree |
| Liver carcinoma | 0.003800186 | 14 | 0 | BeFree |
联系方式
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话： 0531-88819269
E-mail: product@genelibs.com
微信公众号
关注微信订阅号，实时查看信息，关注医学生物学动态。
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备13024435号-2
